Reglicat
Antineoplastic. EGFR, tyrosine kinase inhibitor. Indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations.
Therapeutic Area
Oncology
Active Ingredient
Afatinib
Line
Oncology
Dosage Formsv
40 mg coated tablets x 28 units
30mg coated tablets x 28 units
